Latest Neuroendocrine tumor Stories
Somatuline® is the first and only antitumor therapy demonstrating a statistically significant progression-free survival benefit in a combined population of patients with gastrointestinal
- Results show 94% of patients made lifestyle modifications as a result of their NET, including changes to diet, work, physical activities and social life(1) EAST HANOVER, N.J., Nov.
Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers
-- Telotristat etiprate, a Phase 3 compound for the treatment of carcinoid syndrome PARIS and THE WOODLANDS, Texas, Oct.
- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER,
Clinical Trials Will Continue to Play a Key Role in this Growing Market, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
Targeted therapy for pancreatic cancer is based on personalized medicine approach Somerville, Massachusetts (PRWEB) July 15, 2014 ANDARIX Pharmaceuticals,
Lead Candidate Provides Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) March 24, 2014 ANDARIX Pharmaceuticals, a leader
SAINT-GENIS-POUILLY, France, March 4, 2014 /PRNewswire/ -- Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM),
BerriHealth continues to support research for the neuroendocrine tumor and carcinoid cancer community. Portland, Oregon (PRWEB) February 21, 2014 BerriHealth,
- A gift; a largess; a gratuity; a present; a dole.